首页 | 本学科首页   官方微博 | 高级检索  
检索        


FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Authors:V Subbiah  NO Iannotti  M Gutierrez  DC Smith  L Féliz  CF Lihou  C Tian  IM Silverman  T Ji  M Saleh
Institution:1. Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, USA;2. Hematology Oncology Associates of the Treasure Coast, Stuart, USA;3. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA;4. University of Michigan Health System, Ann Arbor, USA;5. Incyte Biosciences International Sàrl, Morges, Switzerland;6. Incyte Corporation, Wilmington, USA;7. O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA;8. Department of Hematology and Oncology, Aga Khan University, Nairobi, Kenya
Abstract:
Keywords:pemigatinib  FGFR  advanced malignancies  phase I/II clinical trial  genomic profiling
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号